bioAffinity Technologies (BIAF) announced a pilot study with Brooke Army Medical Center, BAMC, to evaluate the Company’s proprietary tests under development to identify specific inflammatory biomarkers for asthma and chronic obstructive pulmonary disease, COPD. The study could lead to the development of diagnostic tests designed to help align patients with the most effective treatments and help monitor the drugs’ effectiveness over time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIAF:
- bioAffinity Highlights CyPath Lung Case Avoiding Unnecessary Biopsy
- BioAffinity Technologies releases clinical case on CyPath Lung
- bioAffinity Showcases CyPath Lung Test at Cleveland Clinic
- BioAffinity announces CyPath Lung to be featured at Cleveland Clinic symposium
- bioAffinity Reports Surge in CyPath Lung Test Sales